Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Change in Accured Expenses of $4.7 million for Q1 2026, up 236.76% year-over-year from $1.4 million in Q1 2025, and up 145.48% quarter-over-quarter from -$10.3 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Change in Accured Expenses history runs 10 years deep, the most recent figure standing at $4.7 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 236.76% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $16.6 million (up 170.27% YoY), while the FY2025 annual figure was $8.5 million, down 19.31% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $4.7 million, up from -$10.3 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $16.4 million in Q2 2025, with the low at -$10.3 million in Q4 2025.
- The 5-year median for Change in Accured Expenses is $1.6 million (2022), against an average of $1.6 million.
- Peak annual rise in Change in Accured Expenses reached 3230.83% in 2025, while the deepest fall reached 663.35% in 2025.
- Scholar Rock Holding's Change in Accured Expenses stood at $1.6 million in 2022, then surged by 91.26% to $3.0 million in 2023, then sank by 39.01% to $1.8 million in 2024, then plunged by 663.35% to -$10.3 million in 2025, then jumped by 145.48% to $4.7 million in 2026.
- Business Quant data shows SRRK's Change in Accured Expenses at $4.7 million in Q1 2026, -$10.3 million in Q4 2025, and $5.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Scholar Rock Holding | 7.19 Bn | 7.19 Bn | - | 10.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.22 Mn |
| Mar 31, 2026 | 4.68 Mn |
| Dec 31, 2025 | -10.30 Mn |
| Sep 30, 2025 | 5.74 Mn |
| Jun 30, 2025 | 16.48 Mn |
| Mar 31, 2025 | -3.43 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2024 | 7.25 Mn |
| Jun 30, 2024 | 493,000.00 |
| Mar 31, 2024 | 963,000.00 |
| Dec 31, 2023 | 3.00 Mn |
| Sep 30, 2023 | 3.59 Mn |
| Jun 30, 2023 | -925,000.00 |
| Mar 31, 2023 | -9.59 Mn |
| Dec 31, 2022 | 1.57 Mn |
| Sep 30, 2022 | 5.31 Mn |
| Jun 30, 2022 | 1.60 Mn |
| Mar 31, 2022 | -1.58 Mn |
| Dec 31, 2021 | -457,000.00 |
| Sep 30, 2021 | 2.89 Mn |